

Home / Investors/ News Releases

rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type I Diabetes

rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type I Diabetes

RICHMOND, Va.--(BUSINESS WIRE)--Dec. 2, 2003-- Insmed's (NASDAQ: INSM) rhIGF-I/rhIGFBP-3 (SomatoKine®), has been found by an independent research team to protect from the onset of type 1 diabetes in non-obese diabetic mice. The independent research team found that both free IGF-I and rhIGF-I/rhIGFBP-3 complex were effective in reducing the severity of insulitis, beta cell destruction and delayed the onset of type 1 diabetes, however, Insmed's rhIGF-I/rhIGFBP-3 complex was a significantly more effective treatment in the prevention of type 1 diabetes.

The study, "IGF-I/IGF-Binding Protein-3 (IGFBP-3) Complex: Therapeutic Efficacy and Mechanism of Protection Against Type 1 Diabetes," was conducted by researchers at The Robarts Research Institute and the department of Microbiology and Immunology, University of Western Ontario and published by Endocrinology in a rapid electronic publication, which makes research papers accessible to readers up to 12 weeks prior to printing. The study was supported by grants from the Canadian Institutes of Health Research and the Juvenile Diabetes Research Foundation and led by T.L. Delovitch, the Sheldon H. Weinstein Scientist in Diabetes at the University of Western Ontario.

Please access the abstract of this paper through the Insmed corporate website, <u>www.insmed.com</u>.

More on rhIGF-I/rhIGFBP-3 (SomatoKine®)

Insmed's rhIGF-I/rhIGFBP-3 is a proprietary delivery composition of insulin-like growth factor-I (IGF-I). The novel compound is administered as a once-daily subcutaneous injection, which can restore IGF levels to physiological relevant levels. In diabetic subjects, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant improvement in blood sugar control and a significant reduction in daily insulin use. Following severe burn injury, in both children and adults, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant improvement in muscle protein synthesis and a significant reduction in the inflammatory response associated with the trauma. In recovery from hip fractures, administration of rhIGF-I/rhIGFBP-3 has demonstrated a significant improvement in functional recovery and bone mineral density. rhIGF-I/rhIGFBP-3 is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS), a severe growth disorder.

About Insmed Incorporated

Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit <u>www.insmed.com</u>.

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these

and other risks and uncertainties, actual results may differ materially from those described in this press release.

CONTACT: Insmed Incorporated Baxter Phillips, III, 804-565-3041 bphillips@insmed.com